Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors

R Iezzi, A R Larici, A Posa, F Carchesio, M T Congedo, L Tagliaferri, A Cassano, E D'argento, G Mantini, E Rodolfino, S Margaritora, E Bria, G Tortora, V Valentini, R Manfredi

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To assess the safety and feasibility of computed tomography-guided radiofrequency ablation (CT-guided RFA) in unresectable lung neoplasms, using a new 15G monopolar internally cooled wet electrode.

PATIENTS AND METHODS: 15 consecutive patients with lung neoplasms (< 4 cm), both primary and secondary, unsuitable for or refusing surgery, underwent percutaneous CT-guided RFA using a 15G electrode with a 3-cm exposed tip. The prevalence and grade of adverse events and technical success were evaluated, as well as the extension of the ablation zone, the complete response rates, and the time to progression, determined at CT examination performed 1, 6, and 12 months after the procedure.

RESULTS: A total of 22 lung neoplasms were treated (mean diameter: 28 mm; range: 20-39 mm). Technical success was obtained in all patients, without major complications or intraprocedural deaths. Mild or moderate pneumothorax was registered in 46.7% of patients, while a perilesional hemorrhage was observed in 5/15 cases. During the follow-up period, a complete response was obtained in 19 out of 22 lesions (86.4%) with three partial response, two of them successfully retreated with the same technique.

CONCLUSIONS: Percutaneous RFA using a 15G internally cooled wet electrode is a safe and feasible treatment for unresectable lung neoplasms, with high complete response rates.

Original languageEnglish
Pages (from-to)6554-6561
Number of pages8
JournalEuropean Review for Medical and Pharmacological Sciences
Issue number15
Publication statusPublished - Aug 2019


Dive into the research topics of 'Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors'. Together they form a unique fingerprint.

Cite this